Archive for 2020

  • Isofol reaches 440 patients in global Phase III AGENT study

    GOTHENBURG, Sweden, December 9, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…

    by
  • Isofol presents an abstract at ASCO GI in January 2021

    Isofol announces that an abstract, including arfolitixorin in the ISO-CC-005 study, has been accepted to be presented at ASCO GI…

    by
  • Invitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

    GOTHENBURG, Sweden, November 2, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today…

    by
  • Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

    GOTHENBURG, Sweden, November 2, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) is pleased…

    by
  • 55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study

    GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today provided an…

    by
  • Strengthened patent protection for arfolitixorin in Japan

    GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has announced today…

    by
  • Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today…

    by
  • Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan

    GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) today announced…

    by
  • Isofol’s CEO Ulf Jungnelius has subscribed for all warrants

    GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth Market: ISOFOL), today announced that…

    by
  • A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis

    GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (Nasdaq First North Premier Growth Market: ISOFOL), today announced that 330 patients…

    by